 Short Hills, New Jersey--Newsfile Corp. - September 7, 2022 - Humanigen, Inc. Nasdaq: HGEN Humanigen, a clinical-stage biopharmaceutical company focused on developing lenzilumab LENZ, a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor GM-CSF, today announced presentation and participation in two healthcare focused investor conferences in September 2022. Details of the presentation and panel participation are as follows:H.C. 